Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case

• Guowei Li,

  Affiliations Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, St. Joseph's Hospital, McMaster University, Hamilton, ON, Canada

  ⨯
• Lehana Thabane ,

  * E-mail: holbrook@mcmaster.ca (AH); thabanl@mcmaster.ca (LT)

  Affiliations Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, St. Joseph's Hospital, McMaster University, Hamilton, ON, Canada

  ⨯
• Thomas Delate,

  Affiliations Kaiser Permanente Colorado Clinical Pharmacy Research Team, Aurora, CO, United States of America, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Denver, CO, United States of America

  ⨯
• Daniel M. Witt,

  Affiliation Department of Pharmacotherapy, University of Utah, Salt Lake City, Utah, United States of America

  ⨯
• Mitchell A. H. Levine,

  Affiliations Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, St. Joseph's Hospital, McMaster University, Hamilton, ON, Canada, Division of Clinical Pharmacology & Toxicology, Department of Medicine, McMaster University, Hamilton, ON, Canada

  ⨯
• Ji Cheng,

  Affiliations Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, St. Joseph's Hospital, McMaster University, Hamilton, ON, Canada

  ⨯
• Anne Holbrook

  * E-mail: holbrook@mcmaster.ca (AH); thabanl@mcmaster.ca (LT)

  Affiliations Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, St. Joseph's Hospital, McMaster University, Hamilton, ON, Canada, Division of Clinical Pharmacology & Toxicology, Department of Medicine, McMaster University, Hamilton, ON, Canada

  ⨯